Author:
Ricafort Rosanna,Gorlick Richard
Reference235 articles.
1. Ahuja D, Sáenz-Robles MT, Pipas JM. 2005. SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation. Oncogene. 24:7729–45.
2. Akatsu T, Murakami T, Nishikawa M, Ono K, Shinomiya N, Tsuda E, Mochizuki S, Yamaguchi K, Kinosaki M, Higashio K, Yamamoto M, Motoyoshi K, Nagata N. 1998. Osteoclastogenesis inhibitory factor suppresses osteoclast survival by interfering in the interaction of stromal cells with osteoclast. Biochem Biophys Res Commun 250:229–34.
3. Akatsuka T, Wada T, Kokai Y, Kawaguchi S, Isu K, Yamashiro K, et al. 2002. ErbB2 expression is correlated with increased survival of patients with osteosarcoma. Cancer 94:1397–404.
4. Alberts DS, Muggia FM, Carmichael J, Winer EP, Jahanzeb M, Venook AP, et al. 2004. Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials. Semin Oncol 31:53–90.
5. Anderson PM, Markovic SN, Sloan JA, Clawson ML, Wylam M, Arndt CA, et al. 1999. Aerosol granulocyte macrophage-colony stimulating factor: a low toxicity, lung-specific biological therapy in patients with lung metastases. Clin Cancer Res 5:2316–23.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献